Category: Preventative Cardiology
The study of cardiovascular disease prevention both primary and secondary
Cardiovascular imaging to guide primary prevention.
Prevention of aortic dissection and aneurysm via an ALDH2-mediated switch in vascular smooth muscle cell phenotype.
Aortic aneurysm/dissection (AAD) is a life-threatening disorder lacking effective pharmacotherapeutic remedies. Aldehyde dehydrogenase 2 (ALDH2) polymorphism is tied with various risk factors for AAD including hypertension, atherosclerosis, and hypercholesterolaemia although […]
» Read morePrimary prevention of sudden death with the implantable cardioverter defibrillator: bridging the evidence gap.
Clinical effectiveness of primary prevention implantable cardioverter-defibrillators: results of the EU-CERT-ICD controlled multicentre cohort study.
The EUropean Comparative Effectiveness Research to Assess the Use of Primary ProphylacTic Implantable Cardioverter-Defibrillators (EU-CERT-ICD), a prospective investigator-initiated, controlled cohort study, was conducted in 44 centres and 15 European countries. […]
» Read moreThe Heart-Healthy Avicennian Diet for Prevention of Heart Disease.
2019 vs. 2016 ESC/EAS statin guidelines for primary prevention of atherosclerotic cardiovascular disease.
The 2019 vs. 2016 European Society of Cardiology/European Atherosclerosis Society (ESC/EAS) dyslipidaemia guidelines contains new recommendations for primary prevention with statins; however, the potential impact of these changes is unclear. […]
» Read moreTriglyceride reduction in secondary atherosclerotic cardiovascular disease prevention: core concepts in contemporary therapeutic targeting.
Optimum nutritional strategies for cardiovascular disease prevention and rehabilitation (BACPR).
Nutrition has a central role in both primary and secondary prevention of cardiovascular disease yet only relatively recently has food been regarded as a treatment, rather than as an adjunct […]
» Read moreEuropean Heart Rhythm Association (EHRA) international consensus document on how to prevent, diagnose, and treat cardiac implantable electronic device infections-endorsed by the Heart Rhythm Society (HRS), the Asia Pacific Heart Rhythm Society (APHRS), the Latin American Heart Rhythm Society (LAHRS), International Society for Cardiovascular Infectious Diseases (ISCVID), and the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS).
Pacemakers, implantable cardiac defibrillators, and cardiac resynchronization therapy devices are potentially lifesaving treatments for a number of cardiac conditions but are not without risk. Most concerning is the risk of […]
» Read moreMeta-Analysis of Usefulness of Treatment of Hypercholesterolemia With Statins for Primary Prevention in Patients Older Than 75 Years.
Clinical guidelines from the United States and Europe do not recommend treatment with statins for primary prevention in patients with hypercholesterolemia who are older than 75 years. Data from 35 […]
» Read moreProgress in the prevention and treatment of atherosclerotic cardiovascular disease: two steps forward, one step back.
Click here to read the full article @ European heart journal Subscribe to our email list for regular updates on your chosen specialtyÂ
» Read moreSecondary prevention of cardiovascular disease in China.
We aimed to estimate the current use of secondary prevention drugs and identify its associated individual characteristics among those with established cardiovascular diseases (CVDs) in the communities of China.We studied […]
» Read moreNickel allergy impacts decision-making in secondary prevention of systemic embolism in patients with patent foramen ovale.
The Dapagliflozin And Prevention of Adverse outcomes in Heart Failure trial (DAPA-HF) in context.
Adolescent health and future cardiovascular disability: it’s never too early to think about prevention.
Long-term ticagrelor for secondary prevention in patients with prior myocardial infarction and no history of coronary stenting: insights from PEGASUS-TIMI 54.
PEGASUS-TIMI 54 demonstrated that long-term dual antiplatelet therapy (DAPT) with aspirin and ticagrelor reduced the risk of major adverse cardiovascular events (MACE), with an acceptable increase in bleeding, in patients […]
» Read moreSecondary prevention medications after coronary artery bypass grafting and long-term survival: a population-based longitudinal study from the SWEDEHEART registry.
Abstract: To evaluate the long-term use of secondary prevention medications [statins, β-blockers, renin-angiotensin-aldosterone system (RAAS) inhibitors, and platelet inhibitors] after coronary artery bypass grafting (CABG) and the association between medication […]
» Read moreUsefulness of Aspirin for Primary Prevention of Atherosclerotic Cardiovascular Disease.
Abstract: Aspirin use in the prevention of cardiovascular events has been a mainstay of treatment for decades. However, the use of aspirin in primary prevention of atherosclerotic cardiovascular disease has […]
» Read morePrediction and Prevention of Sudden Death in the Brugada Syndrome.
Abstract: Sudden cardiac death (SCD) secondary to sudden cardiac arrest (SCA) is a leading cause of death in the United States, claiming over a quarter million lives annually, and is […]
» Read moreComparison of Frequency of Atherosclerotic Cardiovascular Disease Events Among Primary and Secondary Prevention Subgroups of the Systolic Blood Pressure Intervention Trial.
Abstract: The Pooled Cohort Equation (PCE) predicts 10-year risk of first-time atherosclerotic cardiovascular disease (ASCVD) events and was incorporated in analyses of a primary and secondary prevention population in the […]
» Read morePromoting physical activity in primary and secondary prevention.
Abstract: Abstract empty Click here to read full article on original source website
» Read moreEmerging glucose-lowering therapies: a guide for cardiologists.
Abstract: In recent large-scale cardiovascular outcome trials, two new classes of glucose-lowering medications-sodium glucose cotransporter-2 inhibitors (SGLT2i) and glucagon-like peptide-1 receptor agonists (GLP-1RAs)-demonstrated cardiovascular benefits in adults with type 2 […]
» Read moreStroke and thromboembolism prevention in atrial fibrillation.
Abstract: Prevention of stroke and systemic thromboembolism remains the cornerstone for management of atrial fibrillation (AF) and flutter. Multiple risk assessment models for stroke and systemic thromboembolism are currently available. […]
» Read morePrevention Guidelines: Does one size fit all?
Abstract: Abstract empty Click here to read full article on original source website
» Read moreLong-term outcomes of chronic coronary syndrome worldwide: insights from the international CLARIFY registry.
Abstract: Over the last decades, the profile of chronic coronary syndrome has changed substantially. We aimed to determine characteristics and management of patients with chronic coronary syndrome in the contemporary […]
» Read moreMortality reduction with physical activity in patients with and without cardiovascular disease.
Abstract: Physical activity has been shown to reduce mortality in a dose-response fashion. Current guidelines recommend 500-1000 metabolic equivalent task (MET)-min per week of regular physical activity. This study aimed […]
» Read moreCharacteristics and Outcomes of Atrial Fibrillation in Patients With Thyroid Disease (from the ARISTOTLE Trial).
Abstract: Whether patients with atrial fibrillation (AF) and thyroid disease are clinically distinct from those with AF and no thyroid disease is unknown. Furthermore, the effectiveness of anticoagulation for prevention […]
» Read morePrognostic Role of Late Gadolinium Enhancement in Patients With Hypertrophic Cardiomyopathy and Low-to-Intermediate Sudden Cardiac Death Risk Score.
Abstract: Sudden cardiac death (SCD) is the most life-threating complication of hypertrophic cardiomyopathy. Guidelines of the European Society of Cardiology (ESC) suggest the implantation of an implantable cardioverter defibrillator in […]
» Read moreStudy of indications for cardiac device implantation and utilisation in Fabry cardiomyopathy.
Abstract: Fabry disease is a treatable X-linked condition leading to progressive cardiomyopathy, arrhythmia and premature death. Atrial and ventricular arrhythmias contribute significantly to adverse prognosis; however, guidance to determine which […]
» Read more